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SHOC2 phosphatase-dependent RAF dimerization
mediates resistance to MEK inhibition
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Targeted inhibition of the ERK-MAPK pathway, upregulated in a majority of human cancers,
has been hindered in the clinic by drug resistance and toxicity. The MRAS-SHOC2-PP1
(SHOC2 phosphatase) complex plays a key role in RAF-ERK pathway activation by depho-
sphorylating a critical inhibitory site on RAF kinases. Here we show that genetic inhibition
of SHOC2 suppresses tumorigenic growth in a subset of KRAS-mutant NSCLC cell lines
and prominently inhibits tumour development in autochthonous murine KRAS-driven lung
cancer models. On the other hand, systemic SHOC2 ablation in adult mice is relatively well
tolerated. Furthermore, we show that SHOC2 deletion selectively sensitizes KRAS- and
EGFR-mutant NSCLC cells to MEK inhibitors. Mechanistically, SHOC2 deletion prevents
MEKi-induced RAF dimerization, leading to more potent and durable ERK pathway sup-
pression that promotes BIM-dependent apoptosis. These results present a rationale for the
generation of SHOC2 phosphatase targeted therapies, both as a monotherapy and to widen
the therapeutic index of MEK inhibitors.
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Oncogenic mutations in RAS genes are found in over 30%of human cancers including lung, colon and pancreaticadenocarcinomas. In addition, RAS proteins play a key
role in many more cancers through indirect activation, for
example, as a result of aberrant signalling by receptor tyrosine
kinases (RTKs), or by inactivation of negative regulators such as
the NF1 tumour suppressor gene. Non-small cell lung carcinoma
(NSCLC), the leading cause of cancer mortality worldwide, has
known driver mutations of nodes on this pathway in ~75% of
cases, including: ~30% KRAS, ~11% EGFR, ~7% BRAF and ~11%
NF1 mutations1.
RAS proteins have been challenging drug targets and extensive
efforts have focused on targeting RAS-effector pathways as a
more tractable alternative2,3. Multiple lines of evidence including
mutual exclusivity of RAS- and BRAF-mutations in many
cancers highlight the RAF-MEK-ERK kinase cascade (ERK-
MAPK pathway) as a key effector of RAS oncogenic properties
and multiple small molecule inhibitors of this pathway have been
developed4. However, RAS-driven tumours remain intractable to
targeted therapies.
RAF and MEK inhibitors have been approved for the treatment
of BRAF V600E/K-mutant melanoma but only show transient
clinical beneﬁt due to the rapid onset of resistance. Current RAF
inhibitors are contraindicated for the treatment of RAS-driven
tumours as they promote RAF dimerization and ERK-activation
in these cells5,6.
MEK inhibitors (MEKi) are highly selective due to their
allosteric mechanism of action but have shown minimal clinical
efﬁcacy against RAS-driven tumours7,8. This is mainly due to
drug resistance and toxicity. The ERK-pathway is regulated by
negative feedbacks at multiple levels including phosphorylation
of negative regulatory sites in RTKs, as well as in RAF kinases
that inhibit RAF dimerization and binding to RAS9–12. Relief of
these negative feedbacks by pharmacological ERK-pathway
inhibition results in signalling rebound and intrinsic resistance.
In addition, the ERK-pathway is a key mediator of G1/S transi-
tion and MEKi’s have a predominantly cytostatic response that
likely facilitates acquisition of drug resistance mechanisms13.
Strikingly, in both RAS- and BRAF-mutant cells, most resistance
mechanisms lead to ERK-pathway reactivation, highlighting the
strong ‘oncogene addiction’ of these cancers to ERK-signalling.
However, the potent pathway suppression required for antitumor
activity is limited by the dose of MEKi that can be administered
safely because of on target toxicity14,15. ERK-activity is essential
for normal tissue homeostasis, and systemic ablation of MEK1/2
or ERK1/2 genes in adult mice leads to death of the animals
from multiple organ failure within 2–3 weeks, even under con-
ditions of partial inactivation16, highlighting the difﬁculties of
inhibiting the ERK-pathway with a therapeutic index. In order
to effectively harness the addiction of RAS-mutant cancers to
ERK-signalling into viable therapies, new signalling nodes as well
as strategies to improve the therapeutic index of current inhibi-
tors are needed17–21.
Activation of RAF Kinases is a highly complex process where
RAS-GTP binding to the RAS Binding Domain (RBD) of RAF is
only the initial step. Dephosphorylation of a conserved inhibitory
site in the N-terminal regulatory domain (ARAF S214, BRAF
S365, CRAF S259, hereby referred as ‘S259) provides an addi-
tional key activating input that facilitates 14–3–3 dissociation and
RAF dimerization22–25. ‘S259’ RAF dephosphorylation is medi-
ated by a ternary phosphatase complex comprised of SHOC2,
MRAS and PP1 (SHOC2 phosphatase complex)26. Gain-of-
function mutations in the RASopathy Noonan Syndrome in
SHOC2, MRAS and PP1, as well as in CRAF (that cluster around
S259), underscore the key role of the SHOC2 complex in RAF
and ERK-pathway regulation27–34.
In this study we show that genetic inhibition of
SHOC2 suppresses tumour development and elongates overall
survival in KRAS-driven Lung adenocarcinoma (LUAD) mouse
models, as well as inhibiting tumorigenic growth in a subset of
KRAS- and EGFR-mutant human cell lines. Furthermore, by
preventing feedback-induced RAF dimerization, combined
SHOC2 and MEK inhibition leads to more potent and sustained
suppression of ERK-signalling that turns an otherwise reversible
cytostatic response to MEKi’s into cell death in RAS-mutant cells.
Crucially, SHOC2 deletion is well tolerated, both at the cellular
level in tissue culture and at the organismal level in adult
mice, suggesting a unique potential to provide a therapeutic
index. Our study uncovers new insights into SHOC2 biology and
reveals inhibition of the SHOC2 phosphatase complex, alone and
in combination with MEKi’s, as a therapeutic strategy to treat
RAS- and EGFR-mutant cancers.
Results
SHOC2 inhibition perturbs tumour growth in lung cancer
models. To study the in vivo role of SHOC2 we have developed
two mouse models of SHOC2 inactivation using Knock-out (KO)
or Knock-in (KI) approaches (Fig. 1a). Because constitutive
SHOC2 deletion is embryonically lethal as shown by us and
others35 we used a conditional strategy whereby SHOC2 alleles
are inactivated upon cre-mediated recombination. A KO model
was generated by ﬂanking exon 4 of SHOC2 with loxP sites,
whereas a KI model for the SHOC2-D175N point mutant was
generated using a minigene strategy whereby wild-type SHOC2
is expressed in a cDNA conﬁguration under its endogenous
promoter and replaced after cre-mediated recombination by
the mutant D175N allele, unable to form a complex with MRAS
and PP126. To validate our genetic models, MEFs derived from
Shoc2ﬂ/ﬂ;CreERT2, and Shoc2D175N;CreERT2 compound mice
were generated and analysed by western blot (Fig. 1b).
To evaluate the effect of SHOC2 inhibition in vivo in an
autochthonous lung cancer model we used the LSL-KrasG12D
model, alone (K model) or in combination with a LSL-
Trp53R172H allele (KP model) that develops a more severe
phenotype compared to the K model36,37. In both models,
activation of Kras, and inactivation of Shoc2 and p53, were
achieved by intranasal delivery of adenovirus-expressing cre.
Shoc2ﬂ/ﬂ and control mice from K and KP models were
sacriﬁced 6-months after adeno-cre delivery and tumour burden
quantiﬁed by lung weight and H&E histology. SHOC2 inactiva-
tion, using either KO or KI models, signiﬁcantly decreased overall
tumour burden, (Fig. 1c–e) and signiﬁcantly, prolonged overall
survival in both K and KP animals (Fig. 1f, g). Importantly,
when recombination of the ﬂoxed Shoc2 allele was analysed in
remaining tumour nodules from Shoc2ﬂ/ﬂ KP mice, a band for
the unrecombined Shoc2ﬂ allele could be detected to various
levels in a majority of these tumours (Fig. 1h) suggesting that at
least a signiﬁcant proportion of Shoc2ﬂ/ﬂ tumours after 6-months
are ‘escapers’16,38,39 further underscoring the key requirement for
SHOC2 in lung tumour development.
To study SHOC2 function in adult tissue homeostasis, Shoc2
KO and KI mice were crossed with animals carrying an
inducible ubiquitously expressed CreERT2 recombinase40. To
induce SHOC2 deletion systemically in vivo, 8- to 12-week old
mice were treated with tamoxifen by oral gavage under conditions
where high level (>80%) recombination efﬁciency was observed
8-weeks after treatment across all tissues examined, except
brain (Fig. 1i, j). At this time none of these mice showed signs
of toxicities, as determined by normal body weight gain or
signs of ill health compared to control animals. Thus whereas
SHOC2 is required for KRAS-driven lung tumour formation,
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systemic SHOC2 inhibition is well tolerated in adult mice, up
to 8–12weeks.
SHOC2 is required for tumorigenic growth of RAS-mutant cell
lines. To further study the role of SHOC2 in the context of lung
tumorigenesis, both shRNA and CRISPR/CAS9 approaches were
used to deplete SHOC2 in a panel of human NSCLC cell lines
(Supplementary Table 1). Serum-starved SHOC2 knock-out
(KO)/Knock-down (KD) cells consistently had higher basal
levels of phospho-S365 BRAF and showed impaired EGF-induced
S365/S259 B/CRAF dephosphorylation and MEK and ERK
phosphorylation. In contrast, RAS activation or S338 CRAF
phosphorylation were unaffected by SHOC2 downregulation
(Fig. 2a, Supplementary Fig. 1a, b). Furthermore, re-expression of
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SHOC2 wild type (wt), but not SHOC2 D175N, which is defective
for phosphatase complex formation with MRAS and PP126,33
decreased P-S365 BRAF levels and fully rescued MEK and ERK
phosphorylation by EGF (Fig. 2a). This is consistent with a role
for SHOC2 in ERK pathway regulation by speciﬁcally depho-
sphorylating the ‘S259’ inhibitory site in RAF kinases26.
SHOC2 ablation had no effect on proliferation in 2D-adhered
cultures in any KO cell line tested, (Fig. 2b, Supplementary
Fig. 2a, f) consistent with SHOC2 not being essential for
anchorage-dependent proliferation41. In contrast, anchorage-
independent proliferation as spheroids was impaired in the
absence of SHOC2 in a subset (3 out of 6) of KRAS-mutant cell
lines (Fig. 2c, d). SHOC2 ablation also selectively inhibited
spheroid growth in isogenic KRASG12V transformed MEFs
(Supplementary Fig. 2b, c). Defective spheroid growth was
rescued in KO cells by re-expression of WT-SHOC2, but not
SHOC2-D175N (Fig. 2e), consistent with a requirement for
SHOC2’s role within a ‘S259’ RAF holophosphatase complex.
Defective spheroid growth correlated with tumour formation in
subcutaneous xenograft assays, as SHOC2 suppression strongly
suppressed xenograft growth of H358 ‘3D sensitive’ cells (Fig. 2f)
but did not have a signiﬁcant effect on A427 ‘3D resistant’
(Fig. 2g) cells. Although SHOC2 deletion had little effect on
subcutaneous xenograft growth of A427 cells, it strongly inhibited
their implantation and/or growth in lung colonization experi-
ments (Fig. 2h). Taken together with in vivo studies in Fig. 1, this
data shows the contribution of SHOC2 to the tumorigenic
properties of RAS-mutant cells is dependent on both the cell type
and the context.
To understand the preferential requirement for SHOC2 on
anchorage-independent growth, we probed lysates of cells grown
in adhered or suspension culture conditions for markers of ERK-
or PI3K/AKT-signalling. AKT activation was downregulated
similarly in both parental and KO cells growing in suspension
consistent with previous reports42,43. On the other hand, whereas
basal ERK-pathway signalling was largely unaffected in SHOC2
KO cells in adhered cultures, it was signiﬁcantly impaired in
suspension cultures (Fig. 2i). Thus, in the context of oncogenic
RAS, SHOC2 preferentially contributes to ERK signalling under
anchorage-independent conditions.
We noted that cell lines resistant to SHOC2 depletion for
spheroid growth (A421, H460, A549) have inactivating mutations
in the LKB1/STK11 tumour suppressor gene (Supplementary
Table 1) as well as retaining higher AKT phosphorylation levels
in suspension (Fig. 2i) suggesting possible molecular mechanisms
of resistance to SHOC2 ablation for anchorage-independent
growth. Re-expression of LKB1 in A427 LKB1-null cells failed to
render them sensitive to SHOC2 depletion, whereas conversely,
LKB1 knockdown failed to overcome SHOC2 requirement for
spheroid growth in H358 ‘3D sensitive’ cells (Supplementary
Fig. 2d, e). Thus, LKB1 status alone does not appear to determine
sensitivity to SHOC2 for 3D growth. On the other hand, ectopic
expression of membrane associated, constitutively activate AKT
(Myr-AKT1), had no effect on ‘SHOC2 3D resistant’ A549 cells
but fully rescued spheroid growth in ‘SHOC2 3D sensitive’ H358
and H1792 SHOC2 KO cell lines (Fig. 2j–l, Supplementary
Fig. 2f-i). Thus, at least in some contexts, increased AKT
signalling may help to overcome SHOC2’s requirement for 3D
growth in RAS-mutant cells.
SHOC2 deletion sensitizes KRAS- and EGFR-mutant cells to
MEKi’s. In order to broaden SHOC2’s properties as a possible
therapeutic target in NSCLC, we set out to identify potential
synthetic lethal interactions with small molecule inhibitors by
screening in the presence or absence of SHOC2. A screen of a
candidate panel of small molecule inhibitors revealed a potent
and selective sensitization to all MEKi’s in the study, upon
SHOC2 deletion, in both H358, (Fig. 3a) and A549 (Supple-
mentary Fig. 3a) KO cells. Cells growing in suspension were more
sensitive to MEKi than in adhered cells (Supplementary Fig. 3b),
in agreement with higher KRAS- and ERK-signalling dependency
in suspension culture44,45. However, SHOC2 deletion lowered
IC50 values to MEKis similarly in both adhered and suspension
culture conditions (Supplementary Fig. 3b) and so viability assays
were performed under adhered conditions.
We next performed similar experiments in additional NSCLC
cell lines encompassing a wider range of driver mutations found
in human LUAD, including KRAS, EGFR and BRAF, as well
as cells without known driver mutations in the ERK-pathway,
(WT). SHOC2 ablation sensitised all KRAS- and EGFR-mutant
NSCLC cell lines tested, except one (H727), to the MEK
inhibitors Selumetinib (Fig. 3b, c, Supplementary Fig. 4a, c) and
Trametinib (Fig. 3c, Supplementary Fig. 3c), but had no effect on
the response of BRAF-mutant or WT cell lines. Interestingly the
H727 cell line, which is extremely sensitive to MEKi, harbours
a potential activating mutation in ARAF (A285D)46 in addition
to KRASG12V.
Sensitization to MEKi’s was also seen in RAS-mutant cancer
cells derived from other tissue types such as MDA-MB-231
(TNBC, KRASG13D), HCT116 (Colorectal, KRASG13D), Pa-
Tu8092 (Pancreatic, KRASG12V) and SK-MEL-2 (Melanoma,
NRASQ61L) but not BRAFV600E HT-29 colorectal cells (Fig. 3b,
Supplementary Fig. 4c). No signiﬁcant changes were seen with
any other inhibitors tested, including those targeting RAF and
ERK-nodes of the ERK-pathway, in both viability and colony
formation assays (Fig. 3c, d). Signiﬁcantly, results observed in
RAS-mutant versus WT human cancer cell lines, were recapitu-
lated upon SHOC2 inactivation in isogenic NL20 immortalized,
nontumorigenic human bronchial epithelial cells (Fig. 3e, f), as
well as in MEFs derived from Shoc2ﬂ/ﬂ;CreERT2 mice (Fig. 3g),
where SHOC2 ablation selectively sensitized cells to the MEKi
Fig. 1 SHOC2 ablation inhibits tumour growth in both the KRASG12D and more malignant KRASG12D;TP53R172H Lung adenocarcinoma (LUAD) mouse
models. a Genetic strategy for the generation of Shoc2ﬂ/ﬂ KO and Shoc2D175N KI mouse models. b Validation of recombination strategy. E6-immortalised
Shoc2ﬂ/ﬂ CreERT2 MEFs were treated with 1 µg/ml 4-OHT for 7-days and lysates analysed by western blot. SHOC2 ablation perturbs growth of KrasG12D
and KrasG12D;p53R172H mouse LUAD. c Lung weight from indicated genotypes 24-weeks post AdenoCre infection. Signiﬁcance is determined using a two
tailed t-test *= < 0.05 **= < 0.01 ***= < 0.001. d Lung sections from (c) were stained with H&E and quantiﬁed for tumour burden as a % of total lung
area. Signiﬁcance as above. e Representative H&E images from (d). Scale bar= 500 µm. f Kaplan-Meier curve of mice with indicated genotypes from
the Kras;p53 mouse model. Statistics were determined by log-rank test *= < 0.05 **= < 0.01 ***= < 0.001. n= 9–14 animals per group g As (f) with
Kras mouse model. n= 6–12 animals per group. h Incomplete SHOC2 recombination (‘escapers’) may account for a signiﬁcant number of tumours arising
in Shoc2ﬂ/ﬂ mice. Cre-mediated recombination was analysed by PCR in the largest nodules isolated from lungs of KRASG12D;p53R172H;Shoc2ﬂ/ﬂ mice
6-months post AdenoCre infection. i Systemic Shoc2 deletion in adult mice is tolerated. 6- to 8-week-old Shoc2ﬂ/ﬂ CreERT2 mice were subject to
treatment of 80mg/kg of Tamoxifen by oral gavage for 10-days, and tissues harvested 8-weeks later to assess Shoc2 protein levels. Representative
ﬁgure from n= 5 animals. j Quantiﬁcation of SHOC2 levels relative to GAPDH loading control in (i)
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10367-x
4 NATURE COMMUNICATIONS |         (2019) 10:2532 | https://doi.org/10.1038/s41467-019-10367-x | www.nature.com/naturecommunications
Selumetinib (but not upon PanRAFi LY3009120) only upon
ectopic expression of KRASG12V.
Sensitization to MEKi’s upon SHOC2 ablation was fully
rescued by re-expression of WT-SHOC2, but not SHOC2-
D175N (Fig. 3h, Supplementary Fig. 3d). Furthermore, over-
expression of SHOC2-independent, phosphorylation-deﬁcient
‘S259A’ RAF-mutants, also diminished the enhanced MEKi
sensitivity (Fig. 3i, j, Supplementary Fig. 3e-f). Taken together,
these observations suggest genetic inhibition of SHOC2 potently
and selectively sensitizes RAS- and EGFR-mutant cells from
different tissue types to MEKis, in a manner consistent with
SHOC2’s function as a RAF ‘S259’ phosphatase.
a b
Exo »
Endo »
Pa
re
nt
al
KO W
T
D
17
5N
– + – + – + – +
3D
P P KOKO PP PKOKO P PKO KOKO P KO
A4
27
H
17
92
H
46
0
A5
49
H
35
8
H
20
09
2D
P KO P KO P KO P KO
A4
27
H
17
92
H
46
0
A5
49
H
35
8
H
20
09
SHOC2
P-MEK
P-ERK
ERK
P-RSK
RSK
P-AKT
P-S6
AKT
GAPDH
H358
SHOC2
A427
SHOC2
A549
SHOC2
Pa
re
nt
al
KO W
T
D
17
5N
EGF 25 ng/ml– + – + – + – +
SHOC2
BRAF
P-BRAF S365
P-MEK
P-ERK
ERK
P-RSK T380
AKT
Pa
re
nt
al
KO W
T
D
17
5N
– + – + – + – +
P-AKT S473
d
c
P
KO
*
*
Parental
SHOC2 KO
shSHOC2
R
el
at
iv
e 
gr
ow
th
 (%
)
co
m
pa
re
d 
to
 p
ar
en
ta
l N
T 
co
nt
ro
l
0
20
40
60
80
100
120
***
***
H460 A549 A427 H358 H1792 H2009
***
P
KO
0
*** <0.0001
10 days
Pa
re
nt
al
SH
O
C2
 
KO
P
KO
0
5.0 × 1009
1.0 × 1010
1.5 × 1010
2.0 × 1010
8.0 × 107
4.0 × 107
n/s
10 days
Subcutaneous Tail-vein
g
i
h
Pa
re
nt
al
SH
O
C2
 K
O
shSCR
shSHOC2
R
el
at
iv
e 
gr
ow
th
 (%
)
co
m
pa
re
d 
to
 p
ar
en
ta
l
Tu
m
ou
r v
ol
um
e 
(m
m3
)
Pa
re
nt
al KO W
T
D
17
5N
0
50
100
******
SHOC2
P KO P KO
P KO P KO
0
50
100
150
200
***
Empty Myr-AKT
Myr-AKT
My
r-A
KT
Empty
Em
pty
P KO
GAPDH
SHOC2
P-AKT
AKT
Parental
SHOC2 KO
Time (h)
(%
) C
on
flu
en
cy
(%
) C
on
flu
en
cy
(%
) C
on
flu
en
cy
(%
) C
on
flu
en
cy
0 50 100
0
50
100
0
50
100
0
50
100
0
50
100
Time (h)
0 50 100 150
H358
A427
Time (days)
0 10 20 30 40 50 60
0
200
400
600
800
1000
shSHOC2
shScr
Parental
SHOC2 KO
Time (h)
0 50 100
A549
Parental
SHOC2 KO
Time (h)
0 50 100
H1792
e
f
j k
l
H358
H358
f
Parental
SHOC2 KO
75
100
100
37
37
37
100
50
50
75
37
37
37
100
100
50
50
37
37
75
50
50
37
600
400
200
600
400
200
Counts Counts
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10367-x ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2532 | https://doi.org/10.1038/s41467-019-10367-x | www.nature.com/naturecommunications 5
SHOC2 is required for ERK activation induced by MEKi’s.
To characterize the molecular mechanisms of sensitization to
MEKis by genetic inhibition of SHOC2, we measured ERK
pathway activation using a dose response with the MEKi Selu-
metinib in H358 cells, either acutely (0.5 h), or for a longer period
(12 h) (Supplementary Fig. 5). IC50 values for MEK and ERK
phosphorylation were unchanged after acute treatment with
Selumetinib (Supplementary Fig. 5a-c). On the other hand,
following 12 h of MEKi treatment (Supplementary Fig. 5d–f)
there is a dose-dependent increase in MEK phosphorylation
consistent with signalling rebound upon feedback relief47,48.
Notably this dose-dependent rebound in P-MEK was impaired
in SHOC2 KO cells and this correlated with more durable
suppression of ERK phosphorylation at lower MEKi doses
(Supplementary Fig. 5d–f).
To study the role of SHOC2 in feedback relief-induced ERK
pathway reactivation a time course of Selumetinib (Fig. 4a) and
Trametinib (Supplementary Fig. 6a) was performed over 72 h
in both KRAS- (A549, H358) and EGFR-mutant (HCC4006)
parental and SHOC2 KO cells. MEKi treatment promotes
dephosphorylation of S365 BRAF peaking after ~12 h of
treatment (Fig. 4a, b). MEK and ERK rebound phosphorylation
were readily detected after 12 h of treatment (Fig. 4a, c) and
increased over time in a cell line dependent-manner. Strikingly,
in SHOC2 KO cells, MEK rebound phosphorylation was
strongly impaired and ERK pathway activity remained potently
suppressed over the 72 h treatment period which correlated with
accumulation of BIM protein compared to parental cells.
We next performed ‘wash-out’ experiments to analyse pathway
reactivation after acute MEKi withdrawal (Fig. 4d–h). After
Selumetinib wash-out in KRAS mutant A549 or A427 cells,
ERK phosphorylation was detected in control cells by 10 min,
peaked at 30 min and approached basal levels by 180 min.
This response is consistent with the phosphorylated (but inactive
when inhibitor-bound) MEK, leading to a wave of ERK
phosphorylation upon MEKi removal before new feedbacks
regenerate a steady state. ERK pathway reactivation at the level
of P-MEK, P-ERK and P-RSK is strongly impaired in SHOC2
KO cells but high basal RAS-GTP or P-S338 CRAF levels
were unaffected (Fig. 4d). P-MEK rebound and delayed ERK
reactivation on MEKi treatment is fully rescued by re-expression
of WT, but not D175N SHOC2 (Supplementary Fig. 6b-c).
In contrast to MEKi, MEK and ERK-phosphorylation, as well
as BIM protein levels after treatment with the PanRAFi
LY3009120 are independent of SHOC2 (Fig. 4f) which correlates
with the sensitization of SHOC2 KO/KD cells to MEK but not
to PanRAFi’s (Fig. 3).
Similar effects are seen across multiple KRAS- and EGFR-
mutant cell lines with both Selumetinib and Trametinib (Fig. 4e,
Supplementary Fig. 6a-e). On the other hand, P-MEK rebound
and ERK reactivation are only minimally affected in WT
H520 and H522 cells in the absence of SHOC2 (Fig. 4g, h).
Furthermore, in wash-out experiments in Shoc2ﬂ/ﬂ;CreERT2
MEFs, ectopic expression of KRASG12V induces a preferential
dependency on SHOC2 for P-MEK rebound and ERK pathway
reactivation after MEKi withdrawal (Supplementary Fig. 6f-h).
Taken together these results strongly suggest that KRAS- and
EGFR-mutant cells are selectively dependent on SHOC2 for
feedback-mediated pathway reactivation upon MEK inhibition.
SHOC2 is required for RAF dimerization induced by MEKi’s.
MEKi treatment stimulates BRAF-CRAF dimerization in KRAS-
mutant cells49. Therefore, to explore molecular mechanisms of
the SHOC2-dependent feedback reactivation response, we per-
formed wash-out experiments as described above and analysed
RAF dimerization by co-immunoprecipitation. Treatment with
both Selumetinib and Trametinib led to a strong induction of
BRAF dimerization with both CRAF and ARAF in control cells
that was almost completely inhibited in SHOC2 KD/KO RAS-
and EGFR-mutant cell lines (Fig. 5a, b). This correlates with
(i) decreased MEKi-induced P-MEK accumulation in the absence
of SHOC2, (ii) dampened rebound phosphorylation of ERK
and ERK substrates, and (iii) more durable pathway inhibition
after MEKi withdrawal (see model Fig. 5h). In contrast however,
the potent RAF dimerization induced by the RAF inhibitor
LY300912050,51 is not affected by loss of SHOC2 (Fig. 5c), in
agreement with LY3009120-induced ERK-reactivation being
independent of SHOC2 (Fig. 4f). Intriguingly, the ERK inhibitor
LY3214996 induced potent BRAF-CRAF dimerization and
MEK rebound phosphorylation that was SHOC2 dependent as
seen with MEKi (Fig. 5d). However, unlike MEKi (but like RAFi)
ERK phosphorylation was unaffected by SHOC2 loss. Thus sus-
tained inhibition of ERK phosphorylation upon SHOC2 loss
is selectively observed when the RAF-MEK-ERK cascade is
inhibited at the level of MEK, but not RAF or ERK, which in turn
correlates with sensitization in viability assays (Fig. 3).
To further assess the role of RAF dimerization, wash-out
experiments were performed in cells where expression of
individual RAF isoforms was inhibited with siRNAs (Fig. 5e).
Knockdown of BRAF or CRAF, but not ARAF partially perturbed
both P-MEK rebound upon Selumetinib treatment and ERK
and RSK reactivation after Selumetinib withdrawal (Fig. 5e, f)52.
Effects of siRNAs on signalling rebound correlate well with
Fig. 2 SHOC2 is required for the tumorigenic growth of RAS-mutant cell lines. a WT- but not D175N-SHOC2 is sufﬁcient to rescue impaired ERK-pathway
response to EGF in SHOC2 KO cells. H358/ A427/A549 parental and SHOC2 KO cells stably expressing WT or D175N-SHOC2 were treated with 25 ng/
ml EGF for 10min and lysates probed as indicated. b SHOC2 deletion has no effect on adhered cell growth of RAS-mutant NSCLC cell lines. Incucyte
growth curves. Representative of n= 3. c SHOC2 KO/KD perturbs anchorage-independent growth of a subset of RAS-mutant NSCLC cell lines. Parental/
SHOC2 KO clones or shSHOC2 transduced cells were seeded under anchorage-independent conditions and growth determined at Day 5 by alamar blue
staining (mean ± SD) (n= 4). ∗p < 0.05, ∗∗p < 0.01 or ∗∗∗p < 0.001 as determined by two tailed t-test. d P/C images of representative spheroids measured
in (c). Scale bar= 200 µm. e Inhibition of anchorage-independent growth in SHOC2 KO H358 cells is rescued by re-expression of WT-, but not D175N-
SHOC2. Cells described in (a) were seeded as (c). f SHOC2 depletion prevents xenograft growth of H358 cells. 5*106 shSCR or shSHOC2 cells were
injected subcutaneously per ﬂank in athymic nude mice (n= 5 animals per group). g–h SHOC2 is dispensable for subcutaneous tumour growth of A427
cells, but is required for growth in orthotopic lung colonization assays. 2.5*106 Parental or SHOC2 KO cells stably expressing luciferase were injected into
SCID mice (g) subcutaneously, n= 4 animals per group, or (h) into lateral tail vein, n= 10 animals per group. Tumour burden was assessed after 10 days
by bioluminescence imaging (mean ± SD). i SHOC2 selectively contributes to ERK signalling under anchorage-independent conditions. Parental and SHOC2
KO cells were seeded in regular or poly-HEMA coated plates for 24 h and lysates probed as indicated. j Inhibition of anchorage independent growth
on SHOC2 depletion in RAS-mutant cells is rescued by MYR-AKT expression. Parental or SHOC2 KO H358 cells with stable expression of Empty vector
or MYR-AKT were seeded in low-attachment plates and growth determined at Day 5 by alamar blue (mean ± SD, n= 4) k P/C images of representative
spheroids measured in (j) at D5. Scale bar= 200 µm. l Lysates of cells in (j) were probed with indicated antibodies
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sensitization in viability assays (Fig. 5g), as knockdown of either
BRAF or CRAF, but not ARAF, sensitise KRAS-mutant NSCLC
cells to MEKi although again not as strongly as SHOC2
knockdown. Collectively, this data highlights the requirement
of SHOC2-dependent BRAF-CRAF dimerization in mediating
signalling rebound upon MEKi treatment.
Combined SHOC2 and MEK inhibition promotes apoptosis in
RAS-mutant cells. To characterize the nature of the increased
sensitivity to MEKi’s in the absence of SHOC2, and assess whe-
ther cytostatic vs cytotoxic effects were at play, growth curves
were generated from cells cultured in the presence of MEKi for
96 h, after which the MEKi was replaced with fresh media.
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MEKi’s inhibit proliferation in a dose-dependent manner with
cytotoxic effects inferred only at the highest concentrations
from the absence of surviving cells that resumed growth after
inhibitor removal. In the absence of SHOC2 however, complete
‘cytotoxic’ effects were seen at concentrations that only had
partial and/or reversible cytostatic effects on control cells (Fig. 6a,
b). When apoptosis was measured after 48 h by Annexin V
staining, signiﬁcant cell death was similarly seen in control cells
only at the highest concentration of MEKi used. However, in
the absence of SHOC2, MEKi-induced apoptosis was more
potent and achieved at lower concentrations (Fig. 6c, d and
Supplementary Fig. 7a-c).
ERK signalling regulates multiple proteins involved in apoptosis
including the pro-apoptotic BH3 proteins BAD and BIM53,54.
More potent ERK suppression by MEKi in the absence of
SHOC2 correlates with increased levels of BIM and cleaved PARP
(Fig. 6e, f). BIM has repeatedly emerged as a key mediator of
apoptosis induced by targeted inhibitors, including MEKi,
in many cancer cells53,54. To address the role of BIM in mediating
SHOC2 sensitization to MEKi, siRNAs were used to inhibit
BIM expression in viability assays. BIM knockdown diminished
the sensitization to MEKi seen in SHOC2 KO cells (Fig. 6g and
Supplementary Fig. 7e) and completely abrogated MEKi induced
apoptosis of SHOC2 KO RAS-mutant cells (Supplementary
Fig. 7d), underscoring BIM as a key mediator of increased
cytotoxicity upon combined SHOC2 deletion and MEK inhibition.
Increased apoptosis in in vitro assays correlated with marked
regressions in an A427 xenograft model. Treatment with a low
dose of the MEKi Trametinib (0.4 mg/kg) that only had a
cytostatic response in tumours from control cells, caused marked
tumour regressions of SHOC2 KD cells that persisted beyond the
treatment window (Fig. 6h, i). Taken together, these observations
show that concomitant genetic SHOC2 inhibition potentiates the
cytotoxic properties of MEKi’s in a BIM-dependent manner and
increases antitumor efﬁcacy in lung cancer cell lines.
Discussion
This study highlights a critical role for SHOC2 as part of the
MRAS-SHOC2-PP1 phosphatase complex for oncogenic ERK
signalling in NSCLC, the leading cause of cancer-related mor-
tality. SHOC2 ablation in both the LSL-KrasG12D, and more
aggressive KrasG12DTrp53R172H LUAD mouse model, potently
suppresses tumour development and extends lifespan, as has been
shown previously for B & CRAF ablation in the LSL-KrasG12D
model39. Similar observations were seen in a SHOC2D175N KI
model, which will more closely phenocopy pharmacological
inhibition of the SHOC2 phosphatase complex in the clinic
(Fig. 1). On the other hand, SHOC2 ablation appears to be
tolerated remarkably well, both in human cells in culture, and
crucially, at the organismal level in adult mice, where animals
appear normal 8-weeks after efﬁcient systemic genetic ablation
(Fig. 1). This is in clear contrast to MEK and ERK core nodes
of the pathway where systemic inhibition leads to fatal toxicities
in adult mice16. SHOC2/Sur-8 was originally identiﬁed in
C. elegans as a positive modulator of the RTK-RAS-ERK-pathway
that unlike RAF/Lin-45, MEK or ERK/Sur-1 genes, is not
essential for organ development but potently suppresses the
phenotype of mutant RAS or high FGFR signalling55,56. Thus,
both C.elegans and mouse genetics highlight how, in the context
of oncogenic RAS, targeting the SHOC2 regulatory node of the
ERK pathway, may have milder toxicity and thus provide better
therapeutic margins than targeting core components such as
RAF, MEK or ERK.
In human cell lines, SHOC2 is dispensable for anchorage-
dependent proliferation, but is required for anchorage-
independent spheroid growth and/or tumorigenic properties in
KRAS-mutant NSCLC cell lines (Fig. 2). Anchorage-independent
growth reveals a SHOC2-dependent contribution to ERK sig-
nalling, not observed in basal adhered culture conditions. This
suggests there must be redundant and/or SHOC2-independent
mechanisms of ERK activation in adhered growth conditions.
Integrin signalling is known to provide a crucial contribution
to PI3K/AKT pathway activation in adhered culture that is lost
in suspension42,43,57,58, and it is likely that SHOC2-independent
mechanisms of ERK activation linked to integrin signalling are
similarly lost in suspension. Furthermore, impaired PI3K/AKT
activation of RAS-mutant cells cultured in suspension may help
unmask SHOC2’s contribution to tumorigenic properties in RAS-
mutant cells: reduced cooperation from other signalling pathways
enhances the dependency on SHOC2-dependent ERK-signalling
for anchorage-independent growth (i.e. ‘RAS oncogene addiction
to SHOC2 in 3D’). Conversely, our data suggests that aberrant
signalling by the PI3K/AKT (and/or other) pathway(s) can
compensate for loss of SHOC2-dependent ERK-signalling under
anchorage-independent conditions, to promote tumorigenic
growth in a cell and context-dependent manner (Fig. 2, Supple-
mentary Fig.2). Regardless, SHOC2’s contribution to tumorigenic
properties in some RAS-mutant human cells lines, as well as to
tumor development in a KRAS-driven mouse LUAD model
suggests targeting SHOC2 in the clinic may have activity as
monotherapy against a subset of RAS-mutant cancers. Genome
wide synthetic lethal studies have also shown a preferential
dependency of RAS-mutant cells for SHOC2 function59,60.
Additionally, we show that SHOC2 deletion sensitizes KRAS-
and EGFR-mutant NSCLC cell lines speciﬁcally to MEK inhibi-
tors. Notably we observe a similar sensitization to MEKi in the
Fig. 3 SHOC2 deletion sensitizes KRAS- and EGFR-mutant cells to MEKi’s. a Viability assays were performed for Parental and SHOC2 KO H358 cells with
indicated inhibitors. The resulting IC50 values are plotted (x-axis), and compared against the fold change between the IC50 values determined for the
Parental versus SHOC2 KO cells (y-axis). b SHOC2 deletion/depletion sensitises RAS- and EGFR-mutant, but not BRAF-mutant or wild-type cell lines
to the MEKi Selumetinib. IC50 values plotted as (a) for either Parental versus SHOC2 KO cells or shSCR versus shSHOC2 cells. *Due to incomplete
knockdown with shRNA, SHOC2 was inhibited in H1395 by siRNA. *er-Erlotinib resistant. Cell lines are grouped by colour code based on driver mutation.
c SHOC2 deletion selectively sensitises KRAS-mutant NSCLC lines to MEK, but not PanRAF or ERK inhibitors. Replicate IC50 values are plotted for
the indicated cell lines comparing Parental versus SHOC2 KO cells (mean ± SD) (n= 3). Signiﬁcance is determined using a two tailed t-test ∗p < 0.05,
∗∗p < 0.01 or ∗∗∗p < 0.001. d SHOC2 deletion sensitises RAS-mutant cells to MEKi’s in colony formation assays. e Nontumorigenic human bronchial NL20
epithelial cells were infected with retrovirus expressing KRASG12V or an empty vector control and viability assays performed with the MEKi Selumetinib
or the PanRAFi LY3009120. f Lysates of Cells from (e) were probed with indicated antibodies. g E6-immortalized MEFs derived from Shoc2ﬂ/ﬂ;CreERT2
mice were infected with retrovirus expressing KRASG12V or an empty vector control and viability assays performed as (e). h Sensitisation of SHOC2
KO NSCLC cell lines to MEKi’s is rescued by re-expression of WT- but not D175N-SHOC2. Viability assays were performed for SHOC2 KO cells after
stable expression of WT-SHOC2, SHOC2 D175N or empty vector control. i Sensitisation of SHOC2 knockout NSCLC cell lines to MEKi’s is rescued
by expression of RAF ‘S259’ phosphorylation-deﬁcient mutants. Viability assays were performed for SHOC2 KO cells after stable expression of S214A
ARAF, S365A BRAF, S259A CRAF or empty vector control. j Lysates of cells from (i) were probed with indicated antibodies
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context of oncogenic RAS in isogenic non-transformed bronchial
epithelial NL20 cells as well as MEFs (Fig. 3). These observations
suggest that rewiring of cellular signalling by oncogenic RAS
(or high RAS-GTP levels by RTK signalling) creates a new syn-
thetic lethal interaction for combined MEK and SHOC2 inhibi-
tion that could be used as a therapeutic strategy against cancers
with high RAS activity. Mechanistically, our results demonstrate
this is due to the requirement for SHOC2 holophosphatase
function for RAF dimerization driven by MEKi-induced feedback
relief in the context of high basal RAS-GTP levels (Figs 4, 5). This
is consistent with a model whereby coordinate inputs provided by
(i) direct RAF binding to RAS-GTP and (ii) SHOC2 complex
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mediated ‘S259’ RAF dephosphorylation is required for RAF
dimerization and efﬁcient ERK pathway activation25,26 (Fig. 5h).
Impaired RAF dimerization in response to MEKi treatment
upon SHOC2 deletion correlates with impaired MEK rebound
phosphorylation and a deeper and more durable suppression of
ERK-signalling after inhibitor withdrawal (Fig. 4a, Supplementary
Fig.6a). We have complemented ‘inhibitor time courses’ with
‘inhibitor wash-out’ experiments as an experimental paradigm to
study ERK reactivation and show that the type of response in
both assays correlate well with sensitization to inhibitors in via-
bility assays: In the absence of SHOC2, feedback relief mediated
ERK-activation is selectively impaired in KRAS- and EGFR-
mutant NSCLC cell lines treated with MEK, but not RAF or ERK
inhibitors (Fig. 4).
CRAF is required for ERK-feedback reactivation52,61. Here we
extend this observation to show that both BRAF and CRAF, but
not ARAF knockdown, impair ERK-pathway reactivation and
sensitize KRAS-mutant NSCLC cell lines to MEKi, although not
as strongly as SHOC2 KD (Fig. 5). A more potent response of
SHOC2 depletion compared to single depletion of BRAF or
CRAF is consistent with SHOC2 functioning as a PanRAF ‘S259’
phosphatase. Our data is consistent with a key role for BRAF-
CRAF dimers as primary mediators of signalling rebound and
resistance to MEKi’s. However, a role for ARAF cannot be fully
excluded as SHOC2 deletion also prevents ARAF-BRAF dimers.
In summary, depending on the node as well as the mechanism of
action of the inhibitor, impaired feedback-mediated RAF
dimerization and ERK-reactivation in the absence of SHOC2
correlates with increased sensitization in viability assays of RAS-
and EGFR-mutant cells and thus provides a good biomarker for
SHOC2 sensitization.
The ERK pathway is a key regulator of G1/S transition and
MEKi’s predominantly exert cytostatic effects, which likely con-
tributes to their poor clinical efﬁcacy and facilitates the selective
pressure to acquire resistance mechanisms53,62. Importantly,
SHOC2 inactivation greatly potentiates apoptosis induced by
MEKi in KRAS-mutant NSCLC cells and this correlates with
complete cytotoxic responses in tissue culture and with marked
tumour regressions in a xenograft model, at MEKi concentrations
that otherwise only induce a reversible cytostatic response (Fig. 6).
ERK signalling regulates multiple proteins involved in apop-
tosis and can control the balance of pro- and antiapoptotic BCL2
proteins to modulate the apoptotic threshold53,54. ERK phos-
phorylation of the pro-apoptotic BH3 proteins BAD and BIM
leads to sequestration by 14–3–3 proteins and protein degrada-
tion63–66. Combined genetic inhibition of SHOC2 and MEK
inhibitor treatment cooperate to increase BIM protein levels
suggesting a biochemical mechanism to reach the apoptotic
threshold (Fig. 4). Furthermore, suppressing BIM expression
strongly inhibits sensitization to MEKis upon SHOC2 deletion
(Fig. 6). Taken together our data is consistent with a model where
the more potent and sustained ERK suppression achieved by co-
targeting SHOC2 and MEK allows pro-apoptotic BH3 proteins
to accumulate to levels required to induce apoptosis.
As seen with SHOC2, intrapathway dual inhibition (vertical
inhibition) at the level of RAF or ERK (MEKi plus RAFi or MEKi
plus ERKi) also impairs feedback reactivation, leads to more
potent and sustained ERK suppression, promotes tumour
regression in preclinical models in RAS-mutant cells49,61,67.
However, on-target toxicity of pharmacological ERK-pathway
inhibition remains the more challenging hurdle for clinical efﬁ-
cacy. It is hard to rationalize how more potent and sustained
pathway suppression by vertical inhibition with MEKi+ RAFi or
MEKi+ ERKi combinations can be less toxic than MEKi alone
and thus signiﬁcantly improve therapeutic margins in RAS-
driven tumours. In clear contrast to the RAF-MEK-ERK core
nodes of the pathway, SHOC2 deletion appears to be tolerated
relatively well, both in tissue culture and crucially at the orga-
nismal level in mice. Whereas systemic ablation of RAF, MEK
or ERK genes in adult mice is not tolerated16,68 SHOC2 KO
mice appear normal 8-weeks after systemic deletion using a
similar model of conditional inactivation. Although the toxicity
of combined systemic SHOC2 and MEK inhibition in vivo
remains to be addressed, our study suggests that uniquely among
other pathway nodes for vertical inhibition, co-targeting the
SHOC2 holophosphatase may overcome MEKi resistance in
RAS-mutant cells and deliver more potent and durable ERK
pathway suppression that drives cytotoxic responses at lower
MEKi doses with less toxicity.
BRAF-mutant cancer cells are not sensitized to MEKi in
the absence of SHOC2, which is consistent with signalling by
oncogenic BRAF being independent of RAF dimerization47,48,69
and therefore of SHOC2 phosphatase function. However,
resistance mechanisms to current clinical RAF inhibitors fre-
quently depend on RAF dimerization that are expected to be
sensitive to SHOC2 inhibition. Several reports support this
possibility67,70 and thus, SHOC2 could also provide a useful
target for combination therapies against BRAF-mutant cancers
in some contexts.
Our results highlight SHOC2 as an attractive therapeutic
target and provide a rationale for the development of pharma-
cological inhibitors of the SHOC2 phosphatase complex. Phos-
phatase inhibitors continue to lag behind kinase inhibitors
in drug discovery, but there is emerging evidence that PP1
holophosphatases represent underexplored targets of pharmaco-
logical inhibition71,72. PP1 functions in complex with over 200
distinct regulatory proteins, with each providing unique proper-
ties and substrate speciﬁcity to the resulting holophosphatase73.
Whereas catalytic inhibitors of PP1 will inhibit hundreds of
holophosphatases and are toxic to cells, inhibition of speciﬁc
holophosphatase complexes is expected to inhibit only depho-
sphorylation of their cognate substrates. There is now indeed
proof-of-concept for allosteric inhibition of a PP1 holopho-
sphatase by small molecules targeting its regulatory subunit74,75.
Inhibitors of the SHOC2 holophosphatase may have activity as
single agent in RAS-driven cancers and widen the therapeutic
index of MEKi alone or in combination with other targeted agents
against the many cancers with high RAS activity.
Fig. 4 SHOC2 is required for feedback relief ERK activation induced by MEKi’s. a SHOC2 deletion impairs ERK-reactivation after treatment with
Selumetinib. Indicated cells were treated with 1 µM Selumetinib and lysates collected at indicated time points. b Quantiﬁcation of P-BRAF/BRAF over time
for cell lines shown in (a) relative to NT control. c Quantiﬁcation of P-ERK/ERK over time for cell lines shown in (a) relative to NT control. d–f SHOC2
deletion impairs MEK, but not PanRAF induced ERK-reactivation. A549 and A427 cells were pre-treated for 12 h with either 1 µM Selumetinib (d) / 100 nM
Trametinib (e) / or 2.5 µM LY3009120 (f). Cells were either lysed at this point (NT - Non Treated, NW - Non washed) or the inhibitor was washed-out for
the indicated time points before lysate collection. Lysates were used to perform RAS-RBD pull downs and the additional cell lysate probed with indicated
antibodies. g H520 cells or h H522 cells, which have no known driver mutations in the ERK pathway show a reduced dependency on SHOC2 for MEKi-
induced ERK-reactivation. Parental or SHOC2 KO H520/H522 cells were treated as (e)
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Methods
Cell culture and generation of stable cell lines. HEK293 (UCL) and NSCLC cells
obtained from the CRUK Central Cell Services facility (Francis Crick) were cul-
tured in DMEM supplemented with 10% FBS at 37 °C under 5% CO2. NL20 cells, a
gift from Charles Swanton’s research group were cultured in Ham’s F12 medium
supplemented with 1.5 g/L sodium bicarbonate, 2.7 g/L glucose, 2.0 mM L-gluta-
mine, 0.1 mM nonessential amino acids, 0.005 mg/ml insulin, 10 ng/ml epidermal
growth factor, 0.001 mg/ml transferrin, 500 ng/ml hydrocortisone and 4% fetal
bovine serum. For EGF stimulation experiments, cells were serum-starved in
DMEM/0% FBS o/n followed by acute treatment with 25 ng/ml EGF.
Lentiviruses shSHOC2 or shSCR were generated by transient transfection of
HEK293 cells with the lentiviral construct, pMD.G (VSV-G expresser) and p8.91
(gag-pol expresser) packaging vectors. Cells were transfected 4 h after seeding with
plasmid DNA and 1 mg/ml polyethylenimine (PEI, Polysciences) mixed at a 1:4
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ratio in OptiMEM (Life Technologies). Virus-containing medium was harvested
24, 48 and 72 h after transfection and supplemented with 5 µg/ml Polybrene
(hexadimethrine bromide, Millipore Sigma). Cells were transduced with lentivirus
and where required, selection was carried out with 2.5 µg/ml puromycin (Sigma).
Ecotropic retroviruses were generated by transient transfection of the Phoenix
ecotropic cell line and virus was collected as above. Cell lines expressing the
ecotropic receptor EcoR were generated by transduction with amphotropic EcoR
retroviruses and selection with Blasticidin.
SHOC2 knockout (KO) cells were generated by transient transfection with
the pSpCas9(BB)-2A-GFP (PX458), a gift from Feng Zhang (Addgene plasmid
#48138), containing a GFP expression cassette and the following gRNA-encoding
sequence targeting exon 3 of SHOC2: 5′-gRNA-3′ GAGCTACATCCAGCGTA
ATG, PAM: AGG. GFP-positive cells were sorted by FACS into 96-well plates and
single-cell clones were ampliﬁed and analysed by western blot to assess SHOC2
protein levels. SHOC2 KO cells were then transduced with lentivirus expressing
an empty vector, FLAG-SHOC2 WT or the FLAG-SHOC2D175N, under
puromycin selection.
siRNA experiments were performed with a pool of 2 oligos at ﬁnal
concentration of 20 nM. Oligos were mixed with optimum and RNAiMax
(ThermoFisher) and added to cells while cells are undergoing attachment. Lysates
were harvested 72 h after si transfection.
Cell proliferation in anchored vs anchorage-independent growth assays. For
growth curves, cells stably expressing shRNAs or CRISPR knockout cells were
seeded in 24-well plates and imaged on the IncuCyte (Essen BioScience). Pictures
were taken every 2 h, with each data point a composite of four different images. For
anchorage independent growth assays, cells were seeded as 8-replicates in low
attachment 384-well plates (Greiner). Plates were read on day 7 post seeding by
Alamar Blue after 3 h of incubation. Cell seeding was optimised so all lines
maintained linear growth over this time.
Cell viability assays. Cells were seeded in 384-well plates (Greiner) and left o/n
to adhere. Cell seeding was optimised so all lines maintained linear growth over
the time frame of the assay. Speciﬁcally H358, H520, H727, SK-MEL-2, H1944
were seeded at 2000 cells per well, MEFs and NL20 cells at 500 cells per well,
whereas all other lines were seeded at a density of 1000 cells per well. The
following day drugs were prepared at 10× concentration as serial dilutions for
single inhibitor treatments. Cells are incubated in the presence of the drug for 96 h.
Cell viability was determined using Cell Titer Glo (Promega) by incubation with
the cells for 10 mins. Cell viability was determined by normalizing inhibitor-
treated samples to DMSO controls. Alternatively cells were seeded for colony
assays in 6-wells at very low conﬂuence, incubated in the presence of drug for 96 h
before adding fresh media and staining with crystal violet 7-days after removal
of the drug.
Flow cytometry. FACS analysis was used as an additional means to quantitate
apoptotic, dead and live cell fractions. Cells were seeded, left to adhere o/n and
treated with inhibitor the following day. After a 48 h incubation period, cells were
harvested and stained with Annexin V-FITC and PI to detect apoptotic cells.
RBD-RAS pull downs/immunoprecipitation (IP) and western blot. Levels of
active GTP-loaded RAS were determined by GST-RAF-1-RBD pull-down assay.
GSTRAF1-RBD fusion proteins 1–149 (Addgene – 13338) were incubated with
glutathione beads for 1 h rotating at 4 °C, before extensive washing in PBS-M lysis
buffer to remove non-bound protein. Cells for RBD-RAS pull downs were lysed
with PBS-M lysis buffer (PBS pH 7.4, 1% w/v Triton X-100, 5 mM MgCl2, 0.1 mM
MnCl2), 1 mM DTT, Protease inhibitor cocktail (Roche) and Phosphatase inhibitor
solution (10 mM NaF, 2 mM Na3VO4, 2 mM Na4P2O7, 2 mM β-glycerophosphate).
Lysates were incubated for 1 h with the GST-RBD beads rotating at 4 °C before
extensive washing in PBS-M lysis buffer to remove non-bound protein.
For endogenous RAF IPs cells were lysed with PBS-E lysis buffer (PBS/1%
Triton X-100/1 mM EDTA/ Protease inhibitor cocktail (Roche) and Phosphatase
inhibitor solution (10 mM NaF, 2 mM Na3VO4, 2 mM Na4P2O7, 2 mM β-
glycerophosphate). Endogenous IPs were performed using combination of the
appropriate antibody and Protein A/G beads (Sigma). Lysates were incubated
for 6 h rotating at 4 °C before extensive washing in PBS-E lysis buffer to remove
non-bound protein.
Immunoprecipitates were drained and resuspended in NuPAGE LDS sample
buffer (Life Technologies). Samples were run on western blot for downstream
analysis. Uncropped versions of the most important immunoblots are shown in
Supplementary Fig. 9–12.
Xenografts. A427 KRAS-mutant NSCLC cells (2.5 × 106 cells) - &+ shSHOC2
were injected subcutaneously into both ﬂanks of 6–8week old female athymic nude
mice. For inhibitor experiments once tumours were established (200 mm3), ani-
mals (5 per group) were treated with vehicle (4-hydroxypropyl methylcellulose),
or Trametinib resuspended in vehicle (0.4 mg/kg daily) for 28-days (No treatment
breaks). Tumours were measured twice weekly by digital callipers and mice
were weighed weekly for adverse effect to treatments. Tumour volume was
calculated using the following formula: tumour volume= (D × d2)/2, in which D
and d refer to the long and short tumour diameter, respectively. Animals were
culled in accordance with licence restrictions.
In vivo bioluminescence imaging. A427 Parental and SHOC2 KO NSCLC
luciferase expressing cells (2.5*106) were injected subcutaneously into the
ﬂanks, or, into the lateral tail vein of 6-week old female SCID/ Beige mice
(Charles River). 10-days post injections mice were subject to Intraparietal injection
with 150 mg/kg of D-Luciferin (GoldBio) dissolved in DPBS. Bioluminescence
imaging (BLI) were acquired after 10 min of luciferin injection at a 5-second
exposure using the IVIS Lumina. Photons per second were quantiﬁed using the
IVIS software.
Generation of SHOC2 KO and SHOC2D175N KI mouse models. SHOC2 mice
were generated by Taconic Artemis. SHOC2 KO model was generated by the
insertion of Lox P sites into exon 4 of endogenous SHOC2. For the generation
of the SHOC2D175N knockin (KI) mouse model we employed a ‘minigene’ strategy
where the wild-type SHOC2 allele is expressed in a cDNA conﬁguration with
a Flag-tag at the N-terminus under the control of the endogenous promoter.
The wild-type SHOC2 cDNA sequence is deleted after cre-mediated recombination
and replaced by the mutant SHOC2D175N allele containing a Myc-tag.
For SHOC2 KO and KI ERT2 models 6-week old mice are treated with 80 mg/
kg tamoxifen treatment in corn oil (Sigma) by oral gavage for 10-days in 2, 5-day
treatment windows with a week break in between.
Lung tumour model. Mixed-gender, 6- to 12-week old KRASG12D;p53R172H;
SHOC2wt/wt, SHOC2ﬂ/wt or SHOC2ﬂ/ﬂ mice were intranasally infected with a
single dose of 2 × 107 pfu Ad-Cre (University of Iowa Vector Core) to induce
tumours. The generation of KRASG12D;p53R172H has been described
previously36,76.
Lungs were isolated at six months post AdenoCre infection. Tumour sections
were ﬁxed in 10% formalin (Sigma) o/n before parafﬁn processing and fractioning.
Fractions were stained for H&E. Burden was quantiﬁed by determining the total
percentage of lung fraction that was tumour at six months. All histopathological
analyses were performed blind by an experienced pathologist (M A E-B.).
Fig. 5 SHOC2 is required for RAF dimerization induced by MEKi’s. a SHOC2 depletion abrogates MEKi-induced RAF dimerization and impairs ERK pathway
reactivation after MEKi withdrawal. shSCR of shSHOC2 H358 cells were pre-treated with 1 µM Selumetinib for 12 h, before the inhibitor was washed-out at
indicated time points and lysates used to perform endogenous RAF IPs. (NT - Non Treated, NW - Non washed). Con= IgG control IP. b As (a) using A549
and HCC4006 cells with a single wash-out time point of 30min. c SHOC2 is required for MEK but not PanRAFi-induced RAF dimerization. Parental and
SHOC2 KO H358 cells were pre-treated with 1 µM Selumetinib, 100 nM Trametinib 2.5 μM LY3009120 and subject to endogenous RAF IPs as (a). d
SHOC2 is required for ERK inhibitor induced RAF dimerization. As (c), H358 cells were treated with 1 μM Selumetinib and 2 μM LY3214996. e B & C but
not ARAF knockdown partially diminish MEKi induced signalling rebound and ERK reactivation. H358 cells transfected with indicated siRNAs were treated
3 days later with 1 µM Selumetinib for 12 h before the inhibitor was washed-out for 30min. (NT - Non Treated, NW - Non washed). f Quantiﬁcation of
P-ERK and P-T380 RSK in (e). g B & C, but not ARAF knockdown partially sensitise H358 cells to Selumetinib. Viability curves for Selumetinib of H358 cells
transfected with siRNAs as in (e). h Schematic to illustrate the requirement of the SHOC2 phosphatase complex for feedback relief ERK-activation on MEKi
treatment. ERK activity in RAS-mutant cells is maintained at steady state by negative feedbacks at multiple levels including RTK and RAF pathway nodes.
MEKi treatment leads to feedback relief ERK-pathway activation that is both dependent upon RAS-GTP and SHOC2 phosphatase-dependent ‘S259’
dephosphorylation for RAF dimerization. Following inhibitor withdrawal, release of this ‘primed’ P-MEK (phosphorylated but unable to activate ERK when
inhibitor-bound) generates a wave of ERK phosphorylation that is dampened by negative feedbacks. Even in the presence of mutant RAS in SHOC2 KO
cells MEKi induced feedback relief RAF dimerization is prevented, leading to reduced P-MEK rebound and more potent and durable ERK inhibition
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Recombination efﬁciency of the SHOC2 allele was tested for by PCR in the
largest lung tumour nodules from each KRASG12D;p53R172H;SHOC2ﬂ/ﬂ mouse
to look for ‘escapers’ (max 2 nodules per animal – where isolation of the nodule
from surrounding tumour was easily permissible).
Mouse embryonic ﬁbroblasts. Mouse Embryonic Fibroblasts (MEFs) were
isolated from R26CreERT2 SHOC2ﬂ/wt mice at p13.5 and plated under standard
culture conditions. MEFs were immortalised with FB-E6 and transformed with
LXSP3 KRASG12V SHOC2. MEFs were treated with 1 µg/ml 4-OHT (Sigma) for
7-days for to induce Cre-recombination for SHOC2 deletion.
Animal husbandry. All mice were maintained in individually ventilated cages
(IVCs). Athymic nude mice received autoclaved food, water and bedding according
to institutional guidelines. All animal experiments were conducted under an
appropriate UK project license in accordance with the regulations of UK home
ofﬁce for animal welfare according to ASPA (animal scientiﬁc procedure Act 1986).
Statistical analysis. Data are presented as mean ± SD unless otherwise stated.
Signiﬁcance was determined with GraphPad Prism 7 software using the Student’s
t-test where ∗p < 0.05, ∗∗p < 0.01 or ∗∗∗p < 0.001.
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Sequences. siRNA sequences - Stealth RNAi Negative Control Medium GC
Duplex (Life Technologies) was used as control oligo. All other siRNAs were
from Qiagen or Life Technologies. SHOC2–1 sense 5′–3′ GCUGCGGAUGCUU-
GAUUUA antisense 5′–3′ AUUUAGUUCGUAGGCGUCG/ SHOC2–2 sense
5′–3′ GAACUUGGACCAGUAUGGUAGAAUU antisense 5′–3′ CUUGAACCU
GGUCAUACCAUCUUAA/ BRAF-1 Sense 5′–3′ AAAGCUGCUUUUCCAGGG
UUU antisense 5′3′ AAACCCUGGAAAAGCAGCUUU/ BRAF-2 sense 5′–3′ AA
AGAAUUGGAUCUGGAUCAU antisense 5′–3′ AUGAUCCAGAUCCAAUUC
UUU CRAF-1 sense 5′–3′ AAGCACGCUUAGAUUGGAAUA antisense 5′–3′
UAUUCCAAUCUAAGCGUGCUU/ CRAF-2 sense 5′–3′ GGAUGUUGAUGGU
AGUACA antisense 5′–3′ UGUACUACCAUCAACAUCC/ ARAF-1 5′–3′ sense
CCGACUCAUCAAGGGACGAAA antisense 5′–3′ GGCUGAGUAGUUCCCUG
CUUU/
shRNA sequences - Clones were obtained from Thermo Scientiﬁc Scramble (non-
silencing) sense 5′–3′CTCTCGCTTGGGCGAGAGTAAG antisense 5′–3′CTTAC
TCTCGCCCAAGCGAGAG/ SHOC2–1 sense 5′–3′ CTGCTGAAATTGGTGAATT
antisense 5′–3′ GACGACTTTAACCACTTAA / SHOC2–3 sense 5′–3′ TCTATTC
TTTGTAATTACC antisense 5′–3′ AGATAAGAAACATTAATGG.
Fig. 6 Combined genetic inhibition of SHOC2 and MEKi treatment promote apoptosis in RAS-mutant cells. a–b SHOC2 deletion lowers the concentration of
MEKi required to prevent re-growth of A427 cells after inhibitor withdrawal. Incucyte growth curves of Parental or SHOC2 KO A427 cells grown in the
presence of a single addition of the indicated concentrations of Trametinib (a) or Selumetinib (b). After 96 h the inhibitor was washed out and cell growth
measured for an additional 4 days by incucyte imaging. c SHOC2 deletion lowers the concentration of the MEKi required to induce apoptosis in H358 cells.
Parental or SHOC2 KO cells were treated with the indicated concentrations of Selumetinib for 48 h and analysed by FACS after PI and Annexin V staining.
Representative proﬁles from n= 2. d Quantiﬁcation of (c) (mean ± SD)(n= 2). e Immunoblot analysis of lysates of H358 cells treated with Selumetinib for
12 h. f Quantiﬁcation of cleaved PARP in (e). g BIM knockdown diminishes the sensitisation of H358 SHOC2 KO cells to Selumetinib. H358 P and SHOC2
KO cells transfected with SCR or BIM siRNAs were treated with Selumetinib on Day 2 post transfection and cell viability assays performed 4 days later. h–i
Combined genetic inhibition of SHOC2 and MEKi treatment promote tumour regressions in A427 xenografts. 2.5*106 shSCR or shSHOC2 A427 cells were
injected into the ﬂanks of nude mice and tumours allowed to reach 200mm³ before treatment with either vehicle or 0.4 mg/kg Trametinib. h Change in
tumour volume after 28 day treatment is presented as a waterfall plot of individual tumours. Signiﬁcance is determined using a two tailed t-test ∗p < 0.05,
∗∗p < 0.01 or ∗∗∗p < 0.001. i Tumour growth over time, Trametinib treatment was stopped after 28 days and tumour growth measured for additional
14 days. n= 6 A427 shSCR/ A427 shSHOC2 vehicle, n= 7 A427 shSCR Trametinib and n= 8 shSHOC2 Trametinib tumours (mean ± SEM)
Table 1 Antibody list
Name Company Catalogue number species Dilution
AKT (pan) Cell Signaling Technology 2920 Mouse 1:2000
AKT P-S473 Cell Signaling Technology 4060 Rabbit 1:2000
ARAF Santa Cruz sc-166771 Mouse 1:1000
ARAF Santa Cruz sc-408 Rabbit 1:1000
β-Actin Santa Cruz sc-47778 Mouse 1:5000
BCL-XL Cell Signaling Technology 2764 Rabbit 1:2000
BIM Cell Signaling Technology 2933 Rabbit 1:2000
BRAF Santa Cruz sc-5284 Mouse 1:2000
BRAF Santa Cruz sc-9002 Rabbit 1:2000
BRAF P-T753 Abcam ab138399 Rabbit 1:500
CRAF Santa Cruz sc-7267 Mouse 1:1000
CRAF BD Biosciences 610152 Mouse 1:1000
CRAF Santa Cruz sc-133 Rabbit 1:1000
CRAF P-S289/296/301 Cell Signaling Technology 9431 Rabbit 1:1000
CRAF P-259 Santa Cruz Sc-101791 Rabbit 1:500
CRAF P-S338 Cell Signaling Technology 9427 Rabbit 1:1000
EGFR Santa Cruz sc-373746 Mouse 1:1000
EGFR P-T669 Cell Signaling Technology 3056 & 8808 Rabbit 1:1000
ERK ½ Cell Signaling Technology 9102 Rabbit 1:1000
ERK ½ Cell Signaling Technology 9107 Mouse 1:1000
ERK 1/2 P-T202/Y204 Cell Signaling Technology 9101 Rabbit 1:1000
FLAG Sigma F1365 Mouse 1:500
GAPDH Santa Cruz sc-47724 Mouse 1:5000
KRAS Santa Cruz sc-30 Mouse 1:500
MCL-1 Cell Signaling Technology 5453 Rabbit 1:1000
MEK1 Santa Cruz sc-6250 Mouse 1:1000
MEK2 Santa Cruz sc-13159 Mouse 1:1000
MEK ½ Cell Signaling Technology 4694 Rabbit 1:1000
MEK 1/2 P-S217/221 Cell Signaling Technology 9121 & 9154 Rabbit 1:1000
MYC-TAG Cell Signaling Technology 9B11 Mouse 1:500
p21 Waf1/Cip1 Cell Signaling Technology 2947 Rabbit 1:1000
Pan-RAS Santa Cruz sc-166691 Mouse 1:1000
PARP BD Biosciences 556494 Mouse 1:1000
PARP (cleaved) Cell Signaling Technology 9541 Rabbit 1:1000
RPS6 P-S235/236 Santa Cruz sc-293144 Mouse 1:1000
RSK1 Santa Cruz sc-231 Rabbit 1:1000
RSK2 Santa Cruz sc-9986 Mouse 1:000
RSK1 P-S380 Cell Signaling Technology 11989 Rabbit 1:1000
RSK P-T359/ S363 Cell Signaling Technology 9344 Rabbit 1:1000
YB1 Santa Cruz sc-398340 Mouse 1:1000
YB1 P-S102 Cell Signaling Technology 2900 Rabbit 1:1000
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Primer sequences. Kras – WT Forward – 5′–3′ GTCTTTCCCCAGCACAGTGC/
MT Forward 5′–3′ AGCTAGCCACCATGGCTTGAGTAAGTCTGCA/ Common
Reverse – CTCTTGCCTACGCCACCAGCTC.
P53 – WT Forward - 5′–3′ TTACACATCCAGCCTCTGTGG/ MT Forward -
5′–3′ AGCTAGCCACCATGGCTTGAGTAAGTCTGCA/ Common Reverse -
5′–3′ CTTGGAGACATAGCCACACTG
SHOC2 conditional KI D175N – 5′–3′ CCATGGACTACAAGGACGACG/
TGATTGTGAGCTACATCCAGGG
SHOC2 conditional KO – 5′–3′ AAACCAGAATGATAGCCAAGCT/ TTGA
TAATCCTGCATTAATGGG
SHOC2 WT – 5′–3′ AGTGAAGCTTGAGTCACCATGAG/ GCCGTTTGA
TGGTATTGTCG
Constructs. pSpCas9(BB)-2A-GFP (PX458) was a gift from Feng Zhang (Addgene
plasmid # 48138).
Raf-1 GST RBD 1–149 was a gift from Channing Der (Addgene plasmid # 13338).
pBABE-FLAG-LKB1 was a gift from Lewis Cantley (Addgene plasmid # 8592).
pLentiX2-PURO-shLKB1-Ms was a gift from Reuben Shaw (Addgene plasmid
# 61231).
Inhibitors. Pimasertib (AS-703026) (S1475), PD0325901 (S1026), LY3214996
(S8534), LY3009120 (S7842), Ulixertinib (7854), SCH772984 (S7101), OSI-906
(Linsitinib) (S1091), A66 (S2636), GDC-0941 (Pictilisib) (S1065), NVP-AEW541
(S1034), Erlotinib (S7786), Ponatinib (AP24534) (S1490), Afatanib (S1011),
MK2206 (S1078), GDC-0068 (Ipatasertib) (S2808), BGJ398 (S2183), Crizotinib
(S1068), RAF265 (S2161), AZD628 (S2746), LY3009120 (S7842) were purchased
from SelleckChem. Trametinib (GSK1120212) (871700–17–3), AZD6244
(Selumetinib) (606143–52–6) were purchased from Generon. Drugs for in vitro
studies were dissolved in DMSO and stored at −20 °C. Drugs for in vivo
studies were made fresh by resuspending compound in 0.5% 4-hydroxypropyl
methylcellulose, 0.2% Tween-80 (Sigma).
Antibody list. BRAF P-S365 was generated by immunisation of rabbits with a
phoshpo-peptide corresponding to the appropriate region of BRAF (Epitomics/
Abcam). SHOC2 antibody was generated as described26. All other antibodies were
sourced and used as indicated in Table 1.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data supporting the ﬁndings of the current study are available within the article and
its Supplementary Information ﬁles or from the corresponding author upon request.
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